SpringWorks Therapeutics

#Cancer drug targets #Collaboration #Drug discovery #Molecular glue degrader #Protein #Rappta Therapeutics #SpringWorks Therapeutics

License agreement for molecular glue targeting PP2A

Rappta Therapeutics, a company developing anti-cancer drugs, has entered a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific protein phosphatase 2A (PP2A) complexes. Rappta’s PP2A-reactivating technologies are developed using high resolution structural data and have the potential to create a new class of anti-cancer… Read More

#Business & Investment #Cancer Research #News

FDA approval
#FDA #Oncology #Regulatory #SpringWorks Therapeutics #Tumours

FDA approves first therapy for rare non-cancerous tumours

SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has become the first drug to be approved for desmoid tumours in the US, following the go-ahead from the US Food and Drug Administration (FDA). Desmoid tumours are non-cancerous but can be locally aggressive. Although surgical removal has historically been the treatment… Read More

#News #Regulatory